Psychedelic Research Recap May 2023
MDMA & LSD, masking ketamine with anaesthesia, and no blinding. This and more in the May 2023 psychedelic research recap.
Overviews
Psychedelic Research Recap April 2023
April was a month marked by nearly a dozen brain imaging studies on the effects of psychedelics. Jumping out from the pack is the highly anticipated extended DMT study which now has data on the psychological and physiological effects. Other studies (of the 20 total this month) investigate psychedelics for stuttering, its impact on narcissism, and our perception of time.
Psychedelic Research Recap March 2023
March reflected the blossoming of psychedelic research with 23 new articles covered. In this recap, we reflect on the new microdosing study, detailed brain measures under the influence of psychedelics, a null result with psilocybin for depression, and meditation x psychedelics.
Psychedelic Research Recap February 2023
February presented another productive month for psychedelic research. This recap of the 21 most exciting articles covers intracellular neuroplasticity, brain measures, outcomes from psychedelic-assisted therapy (PAT), psychedelics for new indications, and well-being measures.
Psychedelic Research Recap January 2023
This January, outcomes of psychedelic use were closely examined. Studies looked at how experiences are integrated, how challenging experiences lead to growth, and the relationship between psychedelic use and nature-relatedness.
Psychedelic Research Recap December 2022
In December we saw medium dose of psilocybin for depression, paradoxical wakefulness on 5-MeO-DMT, and many ketamine studies.
Psychedelic Research Links December 2022
This is all the other psychedelic research that came out in December 2022. These papers don’t (yet) have their own page in our database.
Psychedelic Research Recap November 2022
In November, we got results of COMPASS Pathways Phase II trial, antidepressants were found to weaken the effects of psilocybin while ketanserin has the potential to stop an LSD trip.
Psychedelic Research Recap October 2022
In October, natural language processing (NLP) was used to successfully predict clinical outcomes using data from a trial exploring psilocybin on treatment-resistant depression (TRD). The first real-world study assessing esketamine for TRD yielded positive results, while new evidence suggests people who microdose may build a tolerance which needs to be taken in future trials.
Psychedelic Research Recap September 2022
Over the past month, we gained some positive insights into the effectiveness ketamine in the real-world data. The official results of the first trial using LSD to treat generalized anxiety disorder were published and researchers continue to learn more about what psychedelics are doing in the brain.